Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 1997

View Archived Issues

Endorex licenses anticancer drug perillyl alcohol

Pfizer enters phase I trials with CP-358774

Stanford announces three studies on leg ischemia treatments

NIH announces discovery of new breast cancer gene

Glucose metabolism gene related to longevity

Palatin meets with FDA on LeuTech

Genetic Evolutionary Nutrition licenses pyruvate

Viazem approved in 10 European countries

DiagnoCure acquires NASBA technology application rights

Gene affecting neurodegeneration cloned

Kinetin clinical data to be presented at IBC symposium

Oxis granted patent application allowance for ergothioneine analogs

Salagen approved for Sjogren's syndrome in Canada

Repaglinide gets expedited review status in U.S

DPP-IV inhibition in the treatment of diabetes

Digestive tract marker evaluated in diabetic patients with gastroenteropathies

Imidazoline derivative displays potent antidiabetic effects in rats

Antidiabetic herbomineral formulation tested in Indian patients

Rapid-acting insulin analog under clinical evaluation

Boston Life Sciences completes phase III trial of Therafectin

EntreMed: Q2 1997 highlights

Merck KGaA begins development of cardioprotectant

Antimigraine agent in pharmacokinetic testing at HMR

GT35 described in patent literature by Kyowa Hakko

Fibrinogen antagonists from Yamanouchi

New antiallergy agents described by Dainippon Ink

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...